February 5, 2016 – The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for multiple myeloma. This report will serve as the basis for deliberation and discussion at the inaugural public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) on May 26, 2016. The Midwest CEPAC is a core program of ICER. ICER’s report for the Midwest CEPAC will focus on adults with multiple myeloma whose disease has not responded to at least one previous line of treatment (i.e., refractory) or has relapsed following such treatment, are not currently on maintenance treatment, and are not being considered for stem cell transplant. It will evaluate the health and economic outcomes of several interventions for multiple myeloma, including:
- Bortezomib (Velcade®, Takeda Millennium)
- Lenalidomide (Revlimid®, Celgene)
- Carfilzomib (Kyprolis®, Onyx) with lenalidomide and dexamethasone
- Daratumumab (Darzalex®, Janssen Biotech) monotherapy
- Elotuzumab (Empliciti®, Bristol Myers-Squibb) with lenalidomide and dexamethasone
- Ixazomib (Ninlaro®, Takeda) with lenalidomide and dexamethasone
- Panobinostat (Farydak®, Novartis Pharmaceuticals Corp.) with bortezomib and dexamethasone
- Pomalidomide (Pomalyst®, Celgene) with low-dose dexamethasone
The scoping document will be open to public comment for a period of one week.
Members of the public are encouraged to submit suggested refinements or additions to the scope via email to email@example.com. Comments must be received by 5:00 PM CST on Friday, February 12 and must adhere to guidelines described in the public comment guide.
During the May 26 Midwest CEPAC public meeting, the independent Council will vote on key questions raised in the reports, and a policy roundtable will discuss recommendations to apply the evidence to policy and practice.
Additional key dates for the draft reports, as well as further information about the May meeting, are included below:
|February 5||Draft scoping document posted|
|February 5- February 12||Public comment on scoping document|
|March 8||Final scoping document posted|
|April 7||Initial draft report and voting questions posted|
|April 7-April 21||Public comment period for draft report and voting questions|
|May 5||Revised draft report and voting questions posted|
|May 26||Public meeting|
|On or about June 24||Final report posted|
Date: May 26, 2016
Location: St. Louis, MO
Additional detail will be posted to the Midwest CEPAC webpage as they become available.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.